Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Kilkari programme aims to offer weekly services, timely accessible, accurate and pertinent 72 audio messages through IVRS about reproductive maternal, neonatal and child health care
Delivers keynote address at the 4th convocation of AIIMS Jodhpur
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
The medical center at the Buddh International Circuit will be under the care of the Indraprastha Apollo Hospital team
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Subscribe To Our Newsletter & Stay Updated